These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38095773)

  • 1. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
    Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
    J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
    Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MR textural analysis on T
    Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
    J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Static and dynamic
    Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
    Santosh V; Rao S
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
    Kebir S; Lazaridis L; Weber M; Deuschl C; Stoppek AK; Schmidt T; Mönninghoff C; Blau T; Keyvani K; Umutlu L; Pierscianek D; Forsting M; Stuschke M; Antoch G; Sure U; Kleinschnitz C; Scheffler B; Colletti PM; Rubello D; Herrmann K; Glas M
    Clin Nucl Med; 2019 Jun; 44(6):e375-e381. PubMed ID: 30985412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
    Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
    Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
    Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating high-grade glioma progression from treatment-related changes with dynamic [
    Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A
    Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
    Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.
    Ninatti G; Sollini M; Bono B; Gozzi N; Fedorov D; Antunovic L; Gelardi F; Navarria P; Politi LS; Pessina F; Chiti A
    Neuro Oncol; 2022 Sep; 24(9):1546-1556. PubMed ID: 35171292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
    Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
    Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.